Development of a target product profile for a point-of-care cardiometabolic device by Vetter, Beatrice et al.
Vetter et al. BMC Cardiovasc Disord          (2021) 21:486  
https://doi.org/10.1186/s12872-021-02298-7
RESEARCH
Development of a target product profile 
for a point-of-care cardiometabolic device
Beatrice Vetter1* , David Beran2, Philippa Boulle3, Arlene Chua3, Roberto de la Tour3, Lucy Hattingh4, 
Pablo Perel5, Gojka Roglic6, Rangarajan Sampath1, Michael Woodman7 and Sigiriya Aebischer Perone2,8 
Abstract 
Introduction: Multi-parameter diagnostic devices can simplify cardiometabolic disease diagnosis. However, exist-
ing devices may not be suitable for use in low-resource settings, where the burden of non-communicable diseases is 
high. Here we describe the development of a target product profile (TPP) for a point-of-care multi-parameter device 
for detection of biomarkers for cardiovascular disease and metabolic disorders, including diabetes, in primary care set-
tings in low- and middle-income countries (LMICs).
Methods: A draft TPP developed by an expert group was reviewed through an online survey and semi-structured 
expert interviews to identify device characteristics requiring refinement. The draft TPP included 41 characteristics with 
minimal and optimal requirements; characteristics with an agreement level for either requirement of ≤ 85% in either 
the survey or among interviewees were further discussed by the expert group and amended as appropriate.
Results: Twenty people responded to the online survey and 18 experts participated in the interviews. Twenty-two 
characteristics had an agreement level of ≤ 85% in either the online survey or interviews. The final TPP defines the 
device as intended to be used for basic diagnosis and management of cardiometabolic disorders (lipids, glucose, 
HbA1c, and creatinine) as minimal requirement, and offering an expanded test menu for wider cardiometabolic 
disease management as optimal requirement. To be suitable, the device should be intended for level 1 healthcare set-
tings or lower, used by minimally trained healthcare workers and allow testing using self-contained cartridges or strips 
without the need for additional reagents. Throughput should be one sample at a time in a single or multi-analyte 
cartridge, or optimally enable testing of several samples and analytes in parallel with random access.
Conclusion: This TPP will inform developers of cardiometabolic multi-parameter devices for LMIC settings, and will 
support decision makers in the evaluation of existing and future devices.
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Background
Although non-communicable diseases (NCDs) are often 
thought to be a problem of high income countries, a 
large proportion of the burden of NCDs is borne by low- 
and middle-income countries (LMICs), with 78% of all 
NCD-related deaths and 85% of premature NCD-related 
deaths in people aged between 30 and 69 years occurring 
in these settings [1, 2]. Cardiovascular diseases (CVDs) 
and metabolic disorders represent a large proportion of 
the NCD burden in LMICs [3, 4], with stroke, ischaemic 
heart disease, diabetes and chronic kidney disease com-
monly appearing in the top ten causes of life years lost 
due to premature mortality [5]. Unlike high-income 
countries, many LMICs lack the healthcare resources to 
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tackle this increasing burden [2, 3]. Primary healthcare, 
with its emphasis on promoting health and preventing 
disease, is the most effective way to reduce premature 
mortality from NCDs [6, 7], but many primary healthcare 
facilities in LMICs lack the laboratory capacity required 
for diagnosis and monitoring of these conditions [8]. As 
such, the World Health Organization (WHO) Global 
Action Plan for NCDs recommends improvement 
of diagnostic services for the four NCDs with the highest 
contribution to morbidity and mortality,  including CVDs 
and diabetes, as well as promotion of development and 
equitable dissemination of affordable, effective and qual-
ity diagnostics for these NCDs [9].
Prevention, diagnosis and management of CVDs and 
diabetes is achieved through the monitoring of various 
laboratory parameters such as lipids as a risk factor for 
atherosclerosis, blood glucose for diabetes, serum cre-
atinine for chronic kidney disease, and liver enzymes for 
liver disease. Based on the results of laboratory tests, best 
treatment options are chosen and dosages are adapted. 
Multi-parameter diagnostic devices, which can test for 
multiple analytes either simultaneously or sequentially 
from a single sample, hold the potential to streamline 
and simplify cardiometabolic disease diagnosis and man-
agement [10]. However, while several multi-parameter 
devices for CVDs already exist, they may not be suit-
able for use in LMICs due to resource requirements (e.g. 
power, storage), the need for trained users, and environ-
mental operating conditions [11].
There is a demonstrated need to develop and adopt 
affordable and effective point-of-care (POC) diagnostic 
tools that are suitable for use in low-resource primary 
care settings, to improve diagnosis and management 
of cardiometabolic disease [12]. Here, we describe the 
development of a target product profile (TPP) for a POC 
multi-parameter device to measure cardiometabolic bio-
markers in LMIC primary care. The TPP aims to define 
the minimal and optimal requirements for a device suit-
able for use in this setting.
Methods
The TPP was developed in three stages: (1) preparation of 
a draft TPP for diagnosis of cardiometabolic diseases by 
an expert group; (2) consensus building through online 
survey and expert interviews to identify device character-
istics for further refinement, and (3) TPP finalization by 
the expert group.
Draft TPP preparation
Baseline TPP requirements were taken from a previously 
developed TPP (version 0) developed by WHO, FIND, 
and MSF, which described desired characteristics of a 
multi-parameter POC polymerase chain reaction (PCR) 
machine to diagnose infection with pathogens causing 
febrile illness [13]. Version 0 included 41 characteris-
tics relating to the scope of the device, the instrument, 
and the assay cartridge, each with minimal and optimal 
requirements. Version 0 had been fully vetted using a 
Delphi-like process, involving a stakeholder survey of 52 
experts followed by a TPP working group discussion  to 
address characteristics with low agreement; the process 
was then repeated, and the revised draft was put forward 
for a month of public consultation on the WHO and 
FIND websites.
For the cardiometabolic device TPP development, an 
expert group was convened to adapt the previously devel-
oped TPP (version 0) to create a draft TPP for diagnosis 
of cardiometabolic diseases (version 1). Members were 
selected from healthcare organizations or academic cen-
tres with an interest in improving health in low-income 
settings, and represented  organizations with relevant 
expertise in NCDs, diagnostics or laboratory work. Areas 
of expertise for each participating expert group member 
are shown in Table  1. The expert group meeting took 
place on 12th December 2019 in Geneva, Switzerland. 
During the meeting, version 0 of the TPP was adapted 
to the context of cardiometabolic non-communicable 
diseases and their management at the primary health-
care level, resulting in amendments to the intended use 
and target use setting characteristics. Device and assay 
cartridge configurations were also adapted to reflect 
the detection of biochemical parameters, rather than 
the PCR nucleic acid amplification techniques used for 
infectious disease. This included amendments to char-
acteristics relating to device design, type of parameters, 
technical aspects for measurement, turnaround times 
and test results. List prices were also adjusted. The result-
ing TPP (version 1) is shown in Additional file 1.
Consensus building
A two-step method was employed to facilitate consensus 
building for the TPP. Firstly, the draft TPP (version 1) was 
reviewed through an online survey. Secondly, semi-struc-
tured stakeholder interviews were performed in order to 
obtain additional feedback on relevant or controversial 
areas.
The online survey was created using  Alchemer, for-
merly Survey Gizmo, software. A link to the online sur-
vey was posted on the FIND LinkedIn account (> 10,000 
followers) and Twitter account (> 7000 followers). Mem-
bers of the expert group also distributed the link amongst 
their respective networks. The survey was open from 14 
February 2020 to 30 April 2020. Survey respondents were 
asked to rate their level of agreement with each of the 41 
minimal and 41 optimal requirements in the draft TPP 
(version 1) using a 5-point Likert scale [14]. Percentage 
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agreement was determined by the number of respond-
ents with a ‘mostly agree’ or ‘fully agree’ rating (score of 
4 or 5), and disagreement with a criterion based on a rat-
ing of ‘fully disagree’, ‘mostly disagree’ or ‘neither agree 
nor disagree’ (scores from 1 to 3), which required a com-
ment from the survey respondent to explain their reasons 
for disagreement. Respondents could provide additional 
comments to accompany scores of 4 or 5 if desired, but 
this was not mandatory.
Clinicians, laboratory experts and procurers of POC 
cardiometabolic devices were targeted for the semi-
structured stakeholder interviews. Eligible participants 
were those who influence or make key decisions on 
purchase or use of POC cardiometabolic devices at the 
primary place of usage, and who self-rate as having at 
least fair or very familiar knowledge with these devices. 
An expert search agency was employed to identify eligi-
ble respondents using a screening questionnaire, aiming 
to match the number of interviewees to the number of 
survey respondents as closely as possible. Interviewees 
were recruited and interviews were conducted between 
June and July 2020. Interviews were performed by video 
call and were aided by a semi-structured discussion 
guide (Additional file  2). Calls were recorded with the 
respondents’ permission and analysis was conducted on 
artificial intelligence-generated transcripts. Notes were 
taken wherever permission for recording was not pro-
vided. Interviews were performed by two employees of 
IQVIA Inc. (Durham, NC, USA). The interviewers were 
experienced in qualitative and quantitative research in 
the healthcare industry, and held social science qualifica-
tions (Bachelor of Arts in Social Science and Master of 
Science in Social Research Methods, respectively). The 
interviewers did not know any of the persons interviewed 
prior to this study.
Interviewees were catergorized into device users, pur-
chase decision makers or both, based on their feedback 
from the screening questionnaire. Interviewees were 
shown 29 of the 41 device characteristics with minimal 
and optimal requirements from version 1 of the TPP, 
relevant to their area of expertise, and asked to iden-
tify the top ten characteristics that were most impor-
tant. The order in which the characteristics were shown 
was rotated for each interviewee to reduce order bias. 
Eleven characteristics were not included in the inter-
views as their requirements were deemed less likely to 
require adaptation due to the stringent baseline defini-
tion (data protection, manufacturing quality, regulatory 
approval, performance criteria, sample volume, mem-
ory). The interviews were qualitative in nature; however, 
characteristics that were mentioned by more than half 
of the interviewees were also quantified. Quantitatively 
rated characteristics were scored as a percentage, with 
the number of interviewees who identified a charac-
teristic as being important to them as the denominator 
and the number who agreed with the minimal or opti-
mal requirement as the numerator. Separate to the TPP 
development, interviewees were also asked to rank the 
characteristics that they identified in  the order of most 
importance.
TPP finalization
To finalize the TPP, the expert group reconvened to dis-
cuss the TPP characteristics with an agreement level 
of ≤ 85% for either the minimal or optimal requirement 
based on either the survey or the interview results. The 
meeting was virtual and took place on 4 September 2020 
Table 1 Expert group expertise and experience
FIND, the global alliance for diagnostics, ICRC International Committee of the Red Cross, LH Lucy Hattingh, LSHTM London School of Hygiene and Tropical Medicine, 
MSF Médecins Sans Frontières, UNHCR United Nations High Commissioner for Refugees, UNIGE/HUG University of Geneva/Hôpitaux Universitaires Genève, WHO World 
Health Organization
Expert affiliation Expertise/role Highest degree
FIND Scientific officer, non-communicable diseases lead PhD
FIND Chief Scientific Officer, technical product development PhD
ICRC Specialist in general internal medicine, humanitarian conflict physician MD
LH Consulting Medical diagnostics business consultant MBA
LSHTM Cardiovascular clinical epidemiologist MD, MSc
MSF Non-communicable diseases advisor and working group leader, physician and interna-
tional public health specialist
MPH
MSF Diagnostics network leader, physician and public health specialist MD, MSc
MSF Laboratory advisor PhD
UNHCR Senior Public Health Officer, humanitarian physician MPH
UNIGE/HUG Lecturer and researcher, public health specialist in NCDs, diabetes and health systems PhD
WHO Medical Officer, physician and epidemiologist MSc
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(two experts were excused). The highest priority char-
acteristics were discussed in detail until agreement was 
reached, while lower priority characteristics were voted 
on by the expert group to achieve a consensus. The 
majority (≥ 50%) of respondents who voted on each char-
acteristic needed to vote in favour of an amendment in 
order for it to be made.
Ethics and consent
As this research did not include human or animal sub-
jects, no ethical or licensing committee approvals or 
informed consent was required. There are no specific 
regulations or guidelines for the development of TPPs, 
however, the methodology used in this study was consist-
ent with protocols for previous TPPs developed by FIND 
and/or WHO.
Results
Online survey and semi‑structured interviews
Of 65 people who accessed the online survey, 20 
responded, of whom 13 provided complete responses. 
Respondents were from 15 countries, and the majority 
were employees of or consultants for non-governmental 
organizations (n = 7) or medical doctors (n = 6) (Table 2). 
For the interviews, eighteen experts agreed to participate. 
The majority were from South Africa (n = 6) and India 
(n = 5), and most were clinical experts (Table 2).
Results from the survey and interviews are shown in 
Fig.  1. In the online survey, of the 41 minimal require-
ments, 14 had an agreement level of ≤ 85%. Minimal 
requirements with the lowest agreement were list price of 
the device (70%), weight of the device (71%), and distri-
bution territory (75%). Of the 41 optimal requirements, 
12 had an agreement level of ≤ 85%. Optimal require-
ments with the lowest agreement were device memory 
(64%), target use setting (69%), target user (71%) and 
training time needed (71%). In the interviews, mini-
mal requirements with a  quantitative assessment that 
had an agreement level of ≤ 85% were service, mainte-
nance and calibration (43%), list price of the device (45%) 
and multiplexing of simultaneous tests (57%). Optimal 
requirements with a quantitative assessment that had an 
agreement level of ≤ 85% were target user (82%), training 
time needed (82%), result output (83%), and specimen 
type (63%). Only two characteristics that had an agree-
ment level of > 85% for either requirement in the online 
survey had an agreement level of ≤ 85% in the interviews 
(multiplexing of simultaneous tests and specimen type).
TPP finalization
In addition to the 22 characteristics with low disagree-
ment in the survey and interviews, the intended use 
characteristic was also discussed during the expert meet-
ing. While there was a high level of agreement on this 
characteristic among the survey respondents and inter-
viewees, the intended use is directly linked to the test 
menu, where agreement was lower. Moreover, survey 
Table 2 Characteristics of online survey respondents and 
interviewees
IVD in vitro diagnostics, NGO non-governmental organization
*National or international
Characteristic Number
















 United States 1
Profession
 Employee/consultant for NGO* 7
 Medical doctor 6
 IVD diagnostics industry personnel 1
 Biomedical Engineer 1
 Consultant 1
 Epidemiologist 1
 Laboratory expert 1
 Nurse 1
 Public Health 1
Interviewees (N = 18)
Country
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Secon Characterisc % agreement % agreement with min n % agreement with opt n % agreement n
Min Opt Min opt
Scope 
General
Intended use 90% 89% 20 19 qualitave
Descripon of the system 87% 75% 15 16 qualitave
Target use seng 94% 69% 17 16 qualitave
Target user 79% 71% 14 14 100% 82% 11
Device Device design 77% 85% 13 13 100% 100% 9
Size 92% 77% 13 13 100% 100% 9
Weight 71% 86% 14 14 100% 100% 9
Power requirements 85% 92% 13 13 100% 100% 7
Throughput 83% 92% 12 13 qualitave
Environmental stability: operang range 83% 92% 12 12 100% 100% 13
Biosafety 100% 100% 12 12
Training me needed 79% 71% 14 14 100% 82% 11
Service, maintenance and calibraon 78% 100% 9 10 43% 93% 14
Paent idenficaon capability 100% 91% 12 11 100% 100% 8
Result output 90% 78% 10 9 100% 83% 13
Data display 100% 92% 13 12 100% 100% 9
Connecvity 92% 92% 13 13 100% 100% 10
Data export and protecon 100% 88% 11 8 qualitave
Memory 82% 64% 11 11
Manufacturing 100% 100% 10 10
List price of the device 70% 100% 10 10 45% 100% 11




Analytes/test menu 89% 78% 9 9 qualitave
Descripon of test cartridge/strip 100% 91% 11 11
Mulplexing of simultaneous tests 90% 90% 10 10 57% 86% 7
Addional third party consumables 82% 100% 11 12
Specimen type 92% 92% 13 13 100% 63% 8
Sample volume 91% 91% 11 11
Limit of detecon 78% 78% 9 9
Interfering substances 83% 83% 6 6
Standardizaon and traceability 100% 100% 10 10
Test result 92% 91% 12 11
Controls 89% 78% 9 9
Environmental Stability: transport 92% 92% 13 12
Environmental Stability: reagent shelf life 91% 90% 11 10 qualitave
Environmental Stability: operang range 91% 91% 12 12 100% 100% 13
Waste/disposal Requirements 100% 100% 9 8
Manufacturing 100% 100% 10 10
Reagent regulatory status 100% 100% 10 10
List price of assay cartridge/strips 90% 100% 10 10 100% 100% 11
Distribuon territory 75% 92% 12 12





























































































Fig. 1 Results from the online survey and semi-structured interviews
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respondents made a range of comments on this ques-
tion, so the experts felt it necessary to revisit discussions 
to confirm the existing description was appropriate. The 
intended use characteristic was modified to clarify that 
the scope of the TPP includes management of people 
with high cardiovascular risk, as well as diagnosis and 
management of people with cardiometabolic disorders.
While some survey respondents and interviewees disa-
greed with the optimal target use setting requirement 
(level 0 health facility without equipped laboratory, elec-
tricity with frequent surges and/or outages, no climate 
control, dusty environment; includes mobile testing facil-
ities; medical staff onsite), experts decided to retain this 
wording, since optimal requirements always define an 
ideal device. The minimal  target user characteristic was 
reworded to clarify that while general laboratory train-
ing was not required for users of the POC device, spe-
cific training for the multi-parameter device would need 
to be provided; for the optimal requirement, users should 
be capable of applying this specific device training. This 
characteristic was renamed ‘target operator’.
In version 1 of the TPP, the minimal requirement for the 
device design characteristic allowed for the test menu to 
be covered by multiple instruments. However, the survey 
respondents felt that this may not be cost effective and 
would introduce redundancy. The expert group therefore 
amended the minimal requirement to require a single 
device to cover the minimal test menu, and the possibility 
for several devices to be connected to run the same tests 
in parallel was moved to the optimal requirement. Addi-
tionally, based on survey feedback that hand-held devices 
have limited added value over small tabletop devices for 
use in primary care settings, and may not be preferred 
due to greater potential for hand-held devices to be lost, 
dropped or misplaced, the optimal requirement for the 
size of the device was amended to require the device to 
be portable rather than hand-held. Weight requirements 
were also amended from ≤ 15 kg to  ≤ 10 kg for the table-
top device (minimal) and from ≤ 1  kg to ≤ 2  kg  for the 
portable device (optimal).
Survey respondents were concerned that operational 
characteristics of the device were not sufficient for coun-
tries in which average summer temperatures are higher 
than 35°C. The temperature ranges were subsequently 
increased; a requirement for the device to be water splash 
proof was also added. Survey respondents and inter-
viewees felt that the training times for users in both the 
minimal and optimal requirements were too optimistic; 
however, they believed that this had been interpreted in 
the context of patient management rather than device 
operation, and so the wording ‘to operate the device’ was 
added to both requirements. Based on interviewee feed-
back, minimal maintenance requirements were changed 
from daily to weekly. Survey respondents commented 
that regional variation in result output should be dis-
couraged; this was therefore removed from the optimal 
requirement.
There was considerable feedback from survey respond-
ents and interviewees regarding the list price of the 
device, with many commenting that the minimal cost of 
5,000 USD would be an extremely high capital invest-
ment for LMIC healthcare centres. Finding the optimal 
trade-off point between affordability and device sophis-
tication is challenging. However, recurrent costs of the 
tests may be more important than device cost, as diag-
nostic devices are often provided free of charge or for a 
small service charge provided that a minimum number 
of tests are purchased within a defined period of time. 
After much debate, the minimal requirement for list 
price of the device was lowered to 1,500 USD, noting that 
a higher price might be acceptable under specific circum-
stances such as reagent lease or rental agreements.
With regards to the test menu characteristic, respond-
ents though  the minimal test menu should include 
explicit result outputs for total cholesterol (TC) and 
high-density lipoprotein (HDL) to calculate low-density 
lipoprotein (LDL), rather than limiting the output to cal-
culated LDL, without specific result output for TC and 
HDL to the user. The minimal requirement was adapted 
accordingly. Survey respondents commented that tro-
ponin may not be a relevant parameter for settings of 
intended use of the device, however, it was decided to 
keep this parameter for optimal requirement  not to 
exclude a use case for the device, even if unlikely. Inter-
viewees thought  that testing of one analyte at a time 
would be too time consuming, however, experts noted 
that the device should allow use of single cartridges to 
permit  individual tests to be conducted at different fre-
quencies and prevent waste. The minimal requirement 
for multiplexing of simultaneous tests was therefore 
changed to ‘Testing of one analyte at a time in single or 
multi-analyte panel cartridge’. Some respondents com-
mented that more interfering substances should be 
included, therefore both requirements were amended to 
state that interference testing should follow Clinical and 
Laboratory Standards Institute (CSLI) EP37 guidance on 
substances and threshold levels [15], as these are interna-
tionally recognized standards.
It was noted that different analytes may require differ-
ent sample types, thus the minimal requirement for fin-
gerstick whole blood may be too restrictive. To allow 
more flexibility around specimen types, the minimal 
requirement was amended to allow for use of plasma, 
serum or urine samples, in addition to whole blood, 
with a limitation of one specimen type per cartridge or 
strip. The optimal requirement was amended to allow 
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for different specimen types per cartridge or strip. The 
sample volume requirement was subsequently changed 
to prescribe a specific volume for fingerstick whole blood 
only, as the most difficult specimen type for which to col-
lect sufficient volume.
Following feedback from online survey respondents 
that the test should not be limited to certain regions, it 
was agreed to change the minimal requirement for distri-
bution territory to ‘worldwide’, and the optimal require-
ment to ‘same as minimal’.
Other minor amendments  included renaming of the 
‘limit of detection’ and ‘description of the system’ char-
acteristics to ‘accuracy’ and ‘description of the device’, 
and clarifying that clinical decision- making based on 
test results should be performed by clinicians/medical 
staff. Overall, minimal and/or optimal requirements were 
adjusted for 18 of the 23 characteristics discussed. The 
final TPP is shown in Table 3.
Ranking of device characteristics
Device characteristic rankings from interviewees are 
shown in Fig. 2. For interviewees who were clinicians or 
potential users of the device (n = 13), the characteristics 
most commonly rated as important were accuracy (pre-
viously limit of detection), result output and environ-
mental stability—operating range. The characteristics 
most  rated among the top three most important were 
accuracy, result output and patient identification capabil-
ity. For interviewees who were purchase decision makers 
(n = 12), the most commonly identified characteristics 
were accuracy, environmental stability—operating range, 
service, maintenance and calibration, and list price of the 
device. These were also the characteristics most com-
monly ranked in the top three.
Discussion
This TPP defines the minimal and optimal requirements 
for a multi-parameter cardiometabolic POC device to be 
used in primary care settings in LMICs. The TPP aims to 
encourage the development of devices for the diagnosis 
and management of cardiovascular diseases and meta-
bolic disorders, conditions that are becoming an increas-
ing burden  in low-resource countries. Additionally, the 
TPP may be used to assess existing multi-parameter 
devices to determine how well they might meet needs in 
LMIC settings [11]. The TPP is intended to be a ‘living 
document’, with requirements to be regularly reviewed 
and adapted to accommodate evolving needs and 
technologies.
While this TPP will inform developers and manufactur-
ers on the key capabilities of a device for use in LMICs, 
we acknowledge that there is no ‘one size fits all’ approach 
to diagnosis and management of cardiometabolic disease 
and risk factors in these settings. Regional features such 
as target population, availability of trained specialists and 
on-site expertise, accessibility of related services, and 
purchase decision-maker requirements, will influence the 
exact needs of each country. The TPP was designed for 
primary care settings; however, primary care facilities 
can vary widely across regions, from basic temporary or 
mobile facilities in humanitarian settings to permanent 
centres with access to laboratory facilities, electricity 
and trained doctors and nurses. The ideal device would 
be usable across all primary care settings. Nevertheless, 
in recognition of the challenges involved in developing 
devices for use in facilities with limited resources, the 
minimal requirement is for level 1 healthcare facilities.
The test menu was designed to address the key car-
diometabolic diseases in LMICs. Glucose and HbA1c 
testing for diagnosis and management of diabetes, 
non-HDL cholesterol testing for atherosclerotic condi-
tions, and creatinine for kidney disease were considered 
the minimal requirements for the device to be of value. 
Optimally, the device would also allow measurement of 
liver enzymes, troponin and brain natriuretic peptide for 
myocardial infarction and heart failure, and glomerular 
filtration rate for kidney function. Other common cardio-
metabolic markers were discussed, including urea, albu-
min, blood ketones and thyroid-stimulating hormone. 
However, to ensure that the TPP requirements were not 
overly restrictive, it was decided to limit the optimal 
requirements to the analytes described above. Indeed, 
some survey respondents felt that there may already be 
too many analytes for a POC device.
Feedback from the expert interviews suggests that 
accuracy of the device will be the primary consideration 
for both clinicians and purchase decision-makers. As the 
results will be used to inform clinical decision making, 
incorrect results could lead to adverse patient outcomes, 
thus quantitively accurate measurements are likely to 
be non-negotiable requirements. Additionally, both cli-
nicians and purchase decision makers emphasized the 
importance of environmental stability, especially for level 
0 healthcare settings. Clinicians also rated patient identi-
fication capability as highly important, in order to allow 
linking of test results with other patient parameters, as 
well as easy-to-interpret result outputs. Purchase deci-
sion makers identified service and maintenance as key 
characteristics, since less frequent maintenance can lead 
to cost savings.
The TPP was developed using a robust multi-step 
process—a standard approach for the generation of such 
documents [16–18]. However, while TPP development 
commonly includes a second round of online surveying, 
this was not deemed necessary  for this TPP, since the 
original TPP had already been fully vetted through both 
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Table 3 Finalized TPP for a multi-parameter cardiometabolic POC device
# Characteristic Min/Opt Requirements
General
1 Intended use Minimal Intended for basic screening, diagnosis and management of 
cardiometabolic disorders (e.g. hyperlipidaemia, diabetes and 
renal function) and also managing people at high cardiovascular 
risk; excluding neonates
1a Optimal Same as minimal, plus offering an expanded test menu to 
address a wider range of cardiometabolic disorders (e.g. liver 
function, acute cardiac care); including neonates
2 Description of device Minimal Benchtop (or hand-held) instrument designed for use in combi-
nation with self-contained, disposable assay cartridge(s) or strips 
containing all required reagents to execute a test from sample 
to result
2a Optimal Same as minimal
3 Target use setting Minimal Level 1 healthcare facility (primary care) defined as having a rudi-
mentary equipped laboratory, water, electricity with intermittent 
surges and/or outages, limited climate control, dusty environ-
ment; medical staff onsite
3a Optimal Level 0 healthcare facility without equipped laboratory, electric-
ity with frequent surges and/or outages, no climate control, 
dusty environment; includes mobile testing facilities; medical 
staff onsite
4 Target operator Minimal Minimally skilled healthcare worker e.g. with basic laboratory 
training (device-specific training provided)
4a Optimal Healthcare worker without specific laboratory training (capable 
of applying device-specific training)
Device
5 Device design Minimal Device with single port capable of interfacing with one cartridge 
design or strip
5a Optimal Device with several ports capable of interfacing with one or 
more cartridge designs or strips for simultaneous, independent 
detection of multiple analytes; possibility for modular connectiv-
ity of several devices
6 Size Minimal Small, table-top device (no larger than 50 × 70 × 50 cm)
6a Optimal Smaller than minimal and portable
7 Weight Minimal ≤ 10 kg
7a Optimal ≤ 2 kg
8 Power requirements Minimal Local 110–220 V AC mains power, plus uninterruptible power 
supply (UPS) to complete current cycle; UPS and circuit protec-
tor must be integrated within the system
8a Optimal Same as minimal, with rechargeable battery back-up (8-h opera-
tion) or single-use battery (for hand-held)
9 Throughput Minimal Throughput processing of one sample at a time; minimum of 
10 samples per hour when individual analytes are tested or 4 
samples per hour when analyte panels are tested
9a Optimal More than one sample at a time with random access and the 
ability to test different analytes simultaneously
10 Environmental Stability: operating range of the device Minimal Operation at 10–40 °C and up to 90% non-condensing humidity 
at an altitude up to 2500 m; able to function in direct sunlight; 
able to withstand dusty conditions; water splash proof
10a Optimal Operation at 5–45 °C and up to 98% non-condensing humidity 
at an altitude up to 3000 m; able to function in direct sunlight; 
able to withstand dusty conditions; water splash proof
11 Biosafety Minimal Closed, self-contained system with unprocessed sample transfer; 
easy decontamination of instrument surfaces
11a Optimal Same as minimal
12 Training time needed Minimal Below 1 day for a healthcare worker to operate the device
12a Optimal Below 2 h for a healthcare worker without basic laboratory train-
ing to operate the device
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Table 3 (continued)
# Characteristic Min/Opt Requirements
13 Service, maintenance and calibration Minimal Weekly maintenance (< 30 min, with hands on time < 10 min); 
mean time between failures of at least 24 months or 10,000 
tests; self-check alerting operator to instrument errors or warn-
ings; operator calibration per new lot or at set time intervals
13a Optimal Weekly maintenance (< 30 min, with hands on time < 10 min); 
mean time between failures of at least 36 months or 30,000 
tests; self-check alerting operator to instrument errors or warn-
ings; ability to be calibrated remotely or no calibration needed 
(factory calibrated)
14 Patient identification capability Minimal Manual entry of alphanumeric patient identifier via keypad, 
touchscreen or connected result management device (e.g. 
smartphone)
14a Optimal Same as minimal, plus bar code, radio frequency identification 
(RFID) or other reader
15 Result output Minimal Quantitative based on the analytes of detection; qualitative 
where this is sufficient to inform clinical decision making
15a Optimal Quantitative plus option of qualitative readout where that result 
is sufficient to inform clinical decision-making; ability to select 
which test results are reported to the user
16 Data display Minimal On-device visual readout with ability to function in various 
lighting conditions ranging from bright to low ambient light 
conditions; ability to add information (patient ID, operator ID, 
date, location, etc.)
16a Optimal Same as minimal, with option to add custom result ranges and 
alerts to support clinical decision-making by medical staff
17 Connectivity Minimal Ability to connect to a mobile network, or Wifi or use a USB for 
data transfer
17a Optimal Same as minimal, including bluetooth and bi-directional com-
munication
18 Data export and protection Minimal Secured data export with end-to-end encryption connectivity to 
external printer; passcode-protected machine access
18a Optimal Same as minimal, plus scheduled/automatic data export using 
interoperable standards; support of any or all of the following 
formats: HL7, FHIR, ASTM, JSON; passcode-protected individual 
user access
19 Memory Minimal 500 patient results, 100 quality control (QC) results
19a Optimal 10,000 patient results, 20,000 QC results or unlimited data stor-
age (cloud-based)
20 Manufacturing Minimal International Organization for Standardization (ISO) 13,485:2016 
compliant
20a Optimal Same as minimal
21 List price of the device Minimal ≤ 1,500$ (USD)
21a Optimal ≤ 300$ (USD)
22 Device regulatory status Minimal Approval through at least one Stringent Regulatory Authority 
(http:// www. stoptb. org/ assets/ docum ents/ gdf/ drugs upply/ 
List_ of_ Count ries_ SRA. pdf )
22a Optimal Same as minimal plus CLIA-waived; WHO-PQ approval if require-
ments are in place
Test cartridge/strip
23 Analytes/test menu Minimal Glucose, HbA1c, lipids (total cholesterol and HDL to calculate 
non-HDL cholesterol), creatinine
23a Optimal Same as minimal and full lipid profile (values for cholesterol, 
HDL, LDL and triglycerides), liver enzymes (ALT, AST, ALP, GGT, 
bilirubin), troponin, BNP, ACR, auto calculation of eGFR and oth-
ers as required for wider cardiometabolic disease management
24 Description of test cartridge/strip Minimal Self-contained, disposable cartridge(s)/strips containing all 
required reagents, buffers or other consumables to execute a 
test from sample to result
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Table 3 (continued)
# Characteristic Min/Opt Requirements
24a Optimal Same as minimal
25 Multiplexing of simultaneous tests Minimal Testing of one analyte at a time in single or multi-analyte panel 
cartridge
25a Optimal Testing of several analytes in parallel, either with multi-analyte 
panel cartridge, or with several cartridge/strip ports; ability to 
measure analytes individually, as well as part of a panel
26 Additional third party consumables Minimal None, except for sample collection
26a Optimal None; manufacturer-provided kits contain all required items for 
sample collection and testing
27 Specimen type Minimal Ability to accept one specimen type per cartridge/strip (whole 
blood or plasma or serum or urine, depending on the param-
eter)
27a Optimal Ability to accept different specimen types per cartridge/strip 
(whole blood, plasma, serum, urine; non-exclusive with excep-
tion of parameter dependency on sample type)
28 Sample volume Minimal Minimum sample volume required to reach clinically relevant 
sensitivities for each test; no more than 50 μl per parameter 
for fingerstick whole blood (cumulative volume for panel 
cartridges)
28a Optimal Same as minimal
29 Accuracy Minimal Equivalent to state of the art reference assays for the same target 
analytes; where applicable, clinically relevant LODs are to be 
met; for troponin, rule-out of myocardial infarction according to 
ACC/AHA guidelines
29a Optimal Same as minimal; for troponin: rule-out of myocardial infarc-
tion according to ESC 2018 guidelines
30 Interfering substances Minimal Interference testing should follow CLSI EP37 list of recom-
mended substances
30a Optimal Same as minimal
31 Standardization and traceability Minimal Test should be standardized based on established methods (e.g. 
isotope dilution mass spectrometry, ID-MS) and traceable to 
internationally recognised reference materials (where available)
31a Optimal Same as minimal
32 Test result Minimal Quantitative result based on the analytes of detection. Qualita-
tive result available to clinician where that result is sufficient to 
inform clinical decision-making
32a Optimal Same as minimal
33 Controls Minimal External positive and negative controls to be run with each new 
lot and every week
33a Optimal External positive and negative controls to be run with each new 
lot and every month
34 Environmental stability: transport Minimal No cold chain required; should be able to tolerate stress during 
transport (cycles of temperature of 30 to 50 °C) without affecting 
the labelled expiry date
34a Optimal Same as minimal
35 Environmental Stability: Reagent shelf life Minimal 18 months at 2–35 °C (including 3 months at 40 °C); 90% relative 
humidity
35a Optimal 24 months at 2–40 °C; up to 98% relative humidity
36 Environmental Stability: Operating range Minimal 10–40 °C; 90% relative humidity
36a Optimal 5–45 °C; 98% relative humidity
37 Waste/disposal Requirements Minimal No components that are classified with a GHS[1] classification—
H(2) that would require waste disposal with high temperature 
incinerator (or more than a De Monfort type incinerator)
37a Optimal Same as minimal
38 Manufacturing Minimal International Organization for Standardization (ISO) 13,485:2016 
compliant
38a Optimal Same as minimal
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a survey and stakeholder interviews, and the first round 
had generated a strong body of evidence for the NCD-
specific characteristics and requirements. Additionally, 
we used an agreement level of ≤ 85% to identify require-
ments for further discussion, which is more stringent 
than the 75% used in similar TPP development processes 
[16–18]. While a large proportion of survey respondents 
from the original TPP (version 0) were clinicians or labo-
ratory experts, they were not necessarily the final users of 
such devices, which is a frequent limitation of TPPs and 
has the potential to influence requirements. We aimed to 
mitigate potential influence of this limitation in the TPP 
by including interviews with clinicians and laboratory 
experts with experience in the use of POC cardiometa-
bolic devices. However, we cannot exclude that a degree 
of such influence persisted from the original TPP, as well 
as the online survey respondents of this TPP.
Our methodology has some limitations, including 
the possibility for bias. For example, the sequence in 
which the characteristics were presented may have led 
to disproportionate importance being placed on certain 
requirements, and the representation of the qualifica-
tions of the survey respondents may have resulted in 
responses being over- or under. The survey design also 
Table 3 (continued)
# Characteristic Min/Opt Requirements
39 Reagent regulatory status Minimal Approval through at least one Stringent Regulatory Authority 
(http:// www. stoptb. org/ assets/ docum ents/ gdf/ drugs upply/ 
List_ of_ Count ries_ SRA. pdf )
39a Optimal Same as minimal plus CLIA-waived; WHO-PQ approval if require-
ments are in place
40 List price of assay cartridge/strips Minimal Strips: ≤ 1$ (USD); cartridges: ≤ 3$ (USD) per analyte (individual 
or as part of a panel)
40a Optimal Strips: ≤ 0.5$ (USD); cartridges: ≤ 1$ (USD) per analyte (individual 
or as part of a panel)
41 Distribution territory Minimal Worldwide
41a Optimal Same as minimal
ACC American College of Cardiology, ACR albumin-to-creatinine ratio, AHA American Heart Association, ALT alanine aminotransferase, ALP alkaline phosphatase, AST 
aspartate aminotransferase, ASTM American Society for Testing and Materials, BNP brain natriuretic peptide, CLIA Clinical laboratory improvement amendments, CSLI 
Clinical and Laboratory Standards Institute, ESC European Society of Cardiology, FHIR fast healthcare interoperability resources, eGFR estimated glomerular filtration 
rate, GGT gamma-glutamyl transferase, GHS globally harmonized system of classification and labelling of chemicals, HbA1c glycated haemoglobin, HDL high-density 
lipoprotein, HL7 health level 7, ID identification, ID-MS isotope dilution mass spectrometry, ISO International Organization for Standardization, JSON JavaScript object 
notation, LDL low-density lipoprotein, LOD limit of detection, RFID radio frequency identification, QC quality control, UPS uninterruptible power supply, USB Universal 
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had the potential to encourage agreement as the quick-
est route to completion. The survey period coincided 
with the beginning of the COVID-19 pandemic, which 
is likely partially responsible for the low response rate, as 
those who would have responded under normal circum-
stances may have had other priorities. Additionally, as a 
large proportion of FIND’s work is related to infectious 
diseases, it is possible that only a limited number of sub-
scribers to the FIND Twitter and LinkedIn accounts had 
relevant expertise in NCDs. Finally, the two-step design 
of the consensus building process allowed for a broad 
representation across countries and stakeholders; how-
ever, there was limited representation from certain high 
population middle-income countries such as China, and 
the geographical differences between the survey respond-
ents and interviewees did not allow for confirmation of 
country-level feedback received at either stage.
Conclusion
In conclusion, this TPP will inform developers and man-
ufacturers considering the development of a cardiometa-
bolic multi-parameter device for LMIC settings and will 
support decision makers to evaluate existing and future 
devices for their fit with TPP requirements.
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